Role of Sox-9, ER81 and VE-Cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Endo, Yoshimi ^a   Deonauth, Kamla ^a,b   Prahalad, Priya ^a   Hoxter, Becky ^a   Zhu, Yuelin ^a   Byers, Stephen W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIGEL; RETINOIC ACID; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR SOX9; VASCULAR ENDOTHELIAL CADHERIN; CADHERIN; COLLAGEN; DNA BINDING PROTEIN; ETV1 PROTEIN, HUMAN; HIGH MOBILITY GROUP PROTEIN; LAMININ; LEUKOCYTE ANTIGEN; PROTEOGLYCAN; SOX-9 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; COCULTURE; COMPLEX FORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; UMBILICAL VEIN; BIOLOGICAL MODEL; BREAST TUMOR; CHEMISTRY; CYTOLOGY; DRUG COMBINATION; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD; BREAST NEOPLASMS; CADHERINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLLAGEN; DNA-BINDING PROTEINS; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH MOBILITY GROUP PROTEINS; HUMANS; LAMININ; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); PROTEOGLYCANS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRETINOIN; UMBILICAL VEINS;

EID: 50549104322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002714     Document Type: Article

References (42)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
2. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
3. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
4. Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE (2000) Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res 2: 417-422.
5. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, et al. (2002) Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 62: 560-566.
6. Shirakawa K, Furuhata S, Watanabe I, Hayase H, Shimizu A, et al. (2002) Induction of vasculogenesis in breast cancer models. Br J Cancer 87: 1454-1461.
7. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, et al. (2008) Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res 68: 1388-1397.
8. Donato LJ, Noy N (2005) Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res 65: 8193-8199.
9. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, et al. (2000) 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res 6: 3696-3704.
10. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, et al. (2006) Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 13: 51-68.
11. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330: 1029-1035.
12. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, et al. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155.
13. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17: 1065-1071.
14. Byers S, Pishvaian M, Crockett C, Peer C, Tozeren A, et al. (1996) Retinoids increase cell-cell adhesion strength, beta-catenin protein stability, and localization to the cell membrane in a breast cancer cell line: a role for serine kinase activity. Endocrinology 137: 3265-3273.
15. Wallez Y, Vilgrain I, Huber P (2006) Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55-59.
16. Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, Huber P (1998) Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem 273: 6750-6755.
17. Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, et al. (2005) The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 24: 2992-3001.
18. Afonja O, Raaka BM, Huang A, Das S, Zhao X, et al. (2002) RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21: 7850-7860.
19. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 2813-2828.
20. Lelievre E, Lionneton F, Soncin F (2001) [Role of the ETS transcription factors in the control of endothelial-specific gene expression and in angiogenesis]. Bull Cancer 88: 137-142.
21. Lelievre E, Mattot V, Huber P, Vandenbunder B, Soncin F (2000) ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene 19: 2438-2446.
22. Lionneton F, Lelievre E, Baillat D, Stehelin D, Soncin F (2003) Characterization and functional analysis of the p42Ets-1 variant of the mouse Ets-1 transcription factor. Oncogene 22: 9156-9164.
23. Cavallaro U, Liebner S, Dejana E (2006) Endothelial cadherins and tumor angiogenesis. Exp Cell Res 312: 659-667.
24. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235: 442-447.
25. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, et al. (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-157.
26. Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P (1997) Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci U S A 94: 6273-6278.
27. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, et al. (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100: 905-911.
28. Liao F, Li Y, O'Connor W, Zanetta L, Bassi R, et al. (2000) Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 60: 6805-6810.
29. Brockes JP (1989) Retinoids, homeobox genes, and limb morphogenesis. Neuron 2: 1285-1294.
30. Langston AW, Gudas LJ (1994) Retinoic acid and homeobox gene regulation. Curr Opin Genet Dev 4: 550-555.
31. Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, et al. (2000) A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet 26: 490-494.
32. Morais DS, Hacker A, Harley V, Goodfellow P, Swain A, et al. (1996) Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. Nat Genet 14: 62-68.
33. Wright E, Hargrave MR, Christiansen J, Cooper L, Kun J, et al. (1995) The Sry-related gene Sox9 is expressed during chondrogenesis in mouse embryos. Nat Genet 9: 15-20.
34. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, et al. (1997) SOX9 directly regulates the type-II collagen gene. Nat Genet 16: 174-178.
35. Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B (1997) SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17: 2336-2346
36. Montero JA, Giron B, Arrechedera H, Cheng YC, Scotting P, et al. (2002) Expression of Sox8, Sox9 and Sox10 in the developing valves and autonomic nerves of the embryonic heart. Mech Dev 118: 199-202.
37. Rahkonen O, Savontaus M, Abdelwahid E, Vuorio E, Jokinen E (2003) Expression patterns of cartilage collagens and Sox9 during mouse heart development. Histochem Cell Biol 120: 103-110.
38. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, et al. (2004) Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A 101: 6502-6507.
39. Breier G, Breviario F, Caveda L, Berthier R, Schnurch H, et al. (1996) Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 87: 630-641.
40. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, et al. (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101-111.
41. Birchmeier C, Birchmeier W, Brand-Saberi B (1996) Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 156: 217-226.
42. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW (1991) Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ 2: 365-372.